Singapore: Singapore based JN Medsys has launched Clarity digital polymerase chain reaction (PCR) for the detection of mutations in cancer or fetal abnormalities, potentially improving the management and outcomes of life-threatening diseases.

Clarity digital PCR system features an innovative chip-in-a-tube design that combines the robustness of chip-based partitioning with the ease-of-use of a tube strip. Each PCR mix is rapidly subdivided into 10,000 partitions by a high-density chip. Up to 8 reactions can be run in parallel to yield 80,000 partitions per tube strip.

Capable of running up to 96 reactions per experiment, more samples can now be analyzed in a day to provide unsurpassed digital PCR throughput. Partitioning can be completed within one minute and is done in-tube without additional equipment or multiple pipetting steps. It is now possible to do more with less - analyze more samples in less time and with less effort.

"Right from the start, we wanted to develop a product that would transform the way digital PCR was carried out. Our aim is to remove all barriers to digital PCR so that more scientists can have access to this powerful technology, and harness it to develop better tests for diseases like cancer or infectious diseases, and to improve the lives of people. We want our Clarity digital PCR system to be the platform technology that enables that. Our purpose at JN Medsys is to make lives better through providing superior products and outstanding service to our community," says Johnson Ng, CEO and founder of JN Medsys.

"We are collaborating with JN Medsys to develop more accurate ways to detect and monitor cancer directly from blood using the ClarityTM digital PCR system. Digital PCR can provide faster and cheaper disease detection, monitoring and clinical care for patients," says Dr Min-Han Tan, team leader and principal research scientist, Institute of Bioengineering and Nanotechnology (IBN).